Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmasset and Roche initiate studies to advance hepatitis drug
The primary objective of the chronic toxicology studies is to assess the safety of R7128 when given for six months. Roche triggered a $7.5 million milestone payment to
The primary objective of the chronic toxicology studies is to assess the safety of R7128 when given for six months. Roche triggered a $7.5 million milestone payment to
Up to 138 (92 orBec and 46 placebo) patients will be enrolled. The primary endpoint of the trial is the proportion of subjects who develop acute GVHD with
The placebo controlled, double-blind Phase II trial conducted in three centers in Europe investigated the efficacy and safety of LAB GHRH applied twice daily subcutaneously (1mg/dose) for 28
This randomized, double-blinded, placebo-controlled study enrolled patients in the US with moderate-to-severe osteoarthritic pain. Following a titration period, patients were randomized to either twice-daily Remoxy (10-80 mg daily)
The trial will be conducted in two parts, both using an open-label, non-controlled design. Eligible patients will include adult patients with advanced newly diagnosed pancreatic cancer. Part A
It is expected that AP23573 will enter into Phase III clinical development for the treatment of metastatic sarcomas beginning this quarter. The agreement provides for an initial payment
The DSMB meets regularly every six months to review unblinded safety data from the two Phase III clinical trials. “The DSMB reviewed safety data of the approximately 3,000
Dr Liu Zhongyi, Lotus CEO and founder, said, “in April 2007, our company invested about $750,000 to develop injectable Ganbifu, which is primarily used for the treatment of
LCP-AtorFen will address three primary cardiovascular risk factors: low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and triglycerides (TG). The trial is designed as a double-blind,
YM says AeroLEF is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. The company